Movement Alert｜CARsgen Therapeutics Rises 5.72% in Regular Trading, In Vivo CAR-T Sector Momentum Fuels Rally

Market Focus

Jun 10

On June 10, CARsgen Therapeutics rose 5.72% in regular trading, trading at HK$15.99/share, with trading volume of HK$61.78 million.

The rally comes amid surging enthusiasm in the in vivo CAR-T therapy sector. Recent industry data revealed breakthrough clinical results from multiple in vivo CAR-T programs, including KLN-1010 achieving 100% overall response rate with all 18 evaluable patients reaching MRD-negative status, and LB2501 demonstrating 100% ORR and 83.3% complete remission in its dose-level-2 cohort. Both programs utilize lentiviral vector technology, the same platform underpinning CARsgen's proprietary CARvivo program KJ-C2529, which targets CD19/CD20 for relapsed/refractory B-NHL and is planned to enter investigator-initiated trials this year.

Additionally, southbound capital has been consistently accumulating shares, with net purchases of 27 million shares over the past 20 trading days, bringing southbound holdings to 27.16% of outstanding shares. This persistent institutional buying provides further support to the stock price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/1121603403"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121603403\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121603403?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 11:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121603403","market":"us","top_or_hot":-1,"title":"Movement Alert｜CARsgen Therapeutics Rises 5.72% in Regular Trading, In Vivo CAR-T Sector Momentum Fuels Rally","media":"Market Focus","content":"<p><p>On June 10, CARsgen Therapeutics rose 5.72% in regular trading, trading at HK$15.99/share, with trading volume of HK$61.78 million.</p><p>The rally comes amid surging enthusiasm in the in vivo CAR-T therapy sector. Recent industry data revealed breakthrough clinical results from multiple in vivo CAR-T programs, including KLN-1010 achieving 100% overall response rate with all 18 evaluable patients reaching MRD-negative status, and LB2501 demonstrating 100% ORR and 83.3% complete remission in its dose-level-2 cohort. Both programs utilize lentiviral vector technology, the same platform underpinning CARsgen's proprietary CARvivo program KJ-C2529, which targets CD19/CD20 for relapsed/refractory B-NHL and is planned to enter investigator-initiated trials this year.</p><p>Additionally, southbound capital has been consistently accumulating shares, with net purchases of 27 million shares over the past 20 trading days, bringing southbound holdings to 27.16% of outstanding shares. This persistent institutional buying provides further support to the stock price.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CARsgen Therapeutics Rises 5.72% in Regular Trading, In Vivo CAR-T Sector Momentum Fuels Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CARsgen Therapeutics Rises 5.72% in Regular Trading, In Vivo CAR-T Sector Momentum Fuels Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-10 11:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 10, CARsgen Therapeutics rose 5.72% in regular trading, trading at HK$15.99/share, with trading volume of HK$61.78 million.</p><p>The rally comes amid surging enthusiasm in the in vivo CAR-T therapy sector. Recent industry data revealed breakthrough clinical results from multiple in vivo CAR-T programs, including KLN-1010 achieving 100% overall response rate with all 18 evaluable patients reaching MRD-negative status, and LB2501 demonstrating 100% ORR and 83.3% complete remission in its dose-level-2 cohort. Both programs utilize lentiviral vector technology, the same platform underpinning CARsgen's proprietary CARvivo program KJ-C2529, which targets CD19/CD20 for relapsed/refractory B-NHL and is planned to enter investigator-initiated trials this year.</p><p>Additionally, southbound capital has been consistently accumulating shares, with net purchases of 27 million shares over the past 20 trading days, bringing southbound holdings to 27.16% of outstanding shares. This persistent institutional buying provides further support to the stock price.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1121603403","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121603403","pubTimestamp":1781062156,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 10, CARsgen Therapeutics rose 5.72% in regular trading, trading at HK$15.99/share, with trading volume of HK$61.78 million.The rally comes amid surging enthusiasm in the in vivo CAR-T therapy...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B"},"translate_title":"动向提示|科济生物常规交易涨5.72%体内CAR-T板块动能助推涨势","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"On June 10, CARsgen Therapeutics rose 5.72% in regular trading, trading at HK$15.99/share, with trading volume of HK$61.78 million.The rally comes amid surging enthusiasm in the in vivo CAR-T therapy sector. Recent industry data revealed breakthrough clinical results from multiple in vivo CAR-T programs, including KLN-1010 achieving 100% overall response rate with all 18 evaluable patients reaching MRD-negative status, and LB2501 demonstrating 100% ORR and 83.3% complete remission in its dose-level-2 cohort. Both programs utilize lentiviral vector technology, the same platform underpinning CARsgen's proprietary CARvivo program KJ-C2529, which targets CD19/CD20 for relapsed/refractory B-NHL and is planned to enter investigator-initiated trials this year.Additionally, southbound capital has been consistently accumulating shares, with net purchases of 27 million shares over the past 20 trading days, bringing southbound holdings to 27.16% of outstanding shares. This persistent institutional buying provides further support to the stock price.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}